Stock Yards Bank Trust Co Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Stock Yards Bank Trust Co reduced its stake in Amgen by 41.4% during the most recent quarter end. The investment management company now holds a total of 8,946 shares of Amgen which is valued at $1,448,357 after selling 6,321 shares in Amgen , the firm said in a disclosure report filed with the SEC on Oct 14, 2016.Amgen makes up approximately 0.20% of Stock Yards Bank Trust Co’s portfolio.

Other Hedge Funds, Including , Vigilant Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 120 additional shares and now holds a total of 1,403 shares of Amgen which is valued at $227,146. Amgen makes up approx 0.04% of Vigilant Capital Management’s portfolio.Centurylink Investment Management Co boosted its stake in AMGN in the latest quarter, The investment management firm added 413 additional shares and now holds a total of 19,499 shares of Amgen which is valued at $3,204,076. Amgen makes up approx 1.10% of Centurylink Investment Management Co’s portfolio.Patten Patten Inctn boosted its stake in AMGN in the latest quarter, The investment management firm added 38 additional shares and now holds a total of 2,832 shares of Amgen which is valued at $465,354. Amgen makes up approx 0.06% of Patten Patten Inctn’s portfolio.Fruth Investment Management reduced its stake in AMGN by selling 10 shares or 0.5% in the most recent quarter. The Hedge Fund company now holds 1,980 shares of AMGN which is valued at $325,354. Amgen makes up approx 0.16% of Fruth Investment Management’s portfolio.

Amgen closed down -2.39 points or -1.45% at $161.9 with 28,17,469 shares getting traded on Friday. Post opening the session at $165.05, the shares hit an intraday low of $161.84 and an intraday high of $165.25 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Oct 14, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Nov 14, 2016 as the ex-dividend date and fixed the record date on Nov 16, 2016. The payable date has been fixed on Dec 8, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.